Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. NVDA
3. TSLA
4. WBD
5. AMD
6. USO
7. META
8. AMC
9. PAA
10. TLT

Go back to Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1165.62 +12.69 (1.10%)
Previous Close $1152.93    52 Week High $88.16 
Open $1144.50    52 Week Low $67.88 
Day High $1168.44    P/E 269.82 
Day Low $1134.41    EPS $4.32 
Volume 885,531